Biocryst Pharmaceuticals (BCRX) Change in Accured Expenses (2010 - 2022)

Biocryst Pharmaceuticals' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$6.3 million for Q4 2022.

• Quarterly Change in Accured Expenses fell 2334.15% year-over-year to -$6.3 million in Q4 2022, while the trailing twelve-month figure through Sep 2022 was $6.6 million (up 6.06% YoY) and the FY2021 annual result came in at $4.2 million, down 38.4% from the prior year.
• Change in Accured Expenses was -$6.3 million for Q4 2022 at Biocryst Pharmaceuticals, down from $6.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.3 million in Q3 2022 and bottomed at -$6.3 million in Q4 2022.
• A 5-year average of $763500.0 and a median of $1.4 million in 2018 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 1782.79% in 2022, while the deepest fall reached 2334.15% in 2022.
• Biocryst Pharmaceuticals' Change in Accured Expenses stood at $1.4 million in 2018, then gained by 4.22% to $1.5 million in 2019, then jumped by 59.76% to $2.4 million in 2020, then plunged by 88.0% to $284000.0 in 2021, then slumped by 2334.15% to -$6.3 million in 2022.
• Business Quant data shows BCRX's Change in Accured Expenses at -$6.3 million in Q4 2022, $6.3 million in Q3 2022, and $284000.0 in Q4 2021.